Universidad de Burgos RIUBU Principal Default Universidad de Burgos RIUBU Principal Default
  • español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
Universidad de Burgos RIUBU Principal Default
  • Ayuda
  • Entre em contato
  • Deixe sua opinião
  • Acceso abierto
    • Archivar en RIUBU
    • Acuerdos editoriales para la publicación en acceso abierto
    • Controla tus derechos, facilita el acceso abierto
    • Sobre el acceso abierto y la UBU
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Navegar

    Todo o repositórioComunidades e ColeçõesPor data do documentoAutoresTítulosAssuntosEsta coleçãoPor data do documentoAutoresTítulosAssuntos

    Minha conta

    EntrarCadastro

    Estatísticas

    Ver as estatísticas de uso

    Compartir

    Ver item 
    •   Página inicial
    • E-Prints
    • Untitled
    • Untitled
    • Artículos ADMIRABLE
    • Ver item
    •   Página inicial
    • E-Prints
    • Untitled
    • Untitled
    • Artículos ADMIRABLE
    • Ver item

    Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10259/8807

    Título
    Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
    Autor
    Valldeoriola Serra, Francesc
    Catalán, María José
    Escamilla-Sevilla, Francisco
    Freire, Eric
    Olivares Romero, Jesús
    Cubo Delgado, EstherAutoridad UBU Orcid
    Calopa, Matilde
    Martínez Martín, Pablo
    Parra, Juan Carlos
    Arroyo, Gloria
    Arbelo, José Matías
    Publicado en
    npj Parkinson's Disease. 2021, V. 7, n. 1
    Editorial
    Springer Nature
    Fecha de publicación
    2021-11
    DOI
    10.1038/s41531-021-00246-y
    Resumo
    Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson’s Disease (APD) patients QoL. Secondarily, the impact on motor symptoms and NMS, emotional well-being, treatment satisfaction, and caregiver QoL, stress, disease burden, anxiety, depression, and work impairment were also investigated. In this prospective, 6-month multicenter postmarketing observational study, LCIG was administered to 59 patients with APD. Endpoints were assessed using validated scales and questionnaires. LCIG significantly improved patient QoL (PDQ-39 mean change ± standard deviation from baseline, −12.8 ± 14.6; P < 0.0001), motor symptoms (UPDRS-III in “On,” −6.5 ± 11.8; P = 0.0002), NMS (NMSS, −35.7 ± 31.1; P < 0.0001), mood (Norris/Bond-Lader VAS, −6.6 ± 21.1; P = 0.0297), fatigue (PFS-16, −0.6 ± 1.0; P = 0.0003), depression (BDI-II, −5.1 ± 9.4; P = 0.0002), anxiety (BAI, −6.2 ± 9.6; P < 0.0001), and patient treatment satisfaction (SATMED-Q, 16.1 ± 16.8; P < 0.0001). There were significant correlations between the change from baseline to 6 months between PDQ-39 and UPDRS-IV, NMSS, BAI, BDI-II, AS, and PFS-16 scores, and Norris/Bond-Lader alertness/sedation factor. Caregiver anxiety also improved (Goldberg anxiety scale, −1.1 ± 1.0; P = 0.0234), but the clinical relevance of this finding is questionable. The serious adverse events reported were similar to those previously described for LCIG. In patients with APD, LCIG improves QoL, motor symptoms and NMS, emotional well-being, and satisfaction with the treatment. Improvement in patient QoL is associated with improvements in motor complications, NMS, anxiety, depression, apathy and fatigue. Improvements in patients’ QoL does not correspond with improvements in caregivers’ QoL or burden.
    Materia
    Sistema nervioso-Enfermedades
    Nervous system-Diseases
    Medicina
    Medicine
    Neurología
    Neurology
    URI
    http://hdl.handle.net/10259/8807
    Versión del editor
    https://doi.org/10.1038/s41531-021-00246-y
    Aparece en las colecciones
    • Artículos ADMIRABLE
    Atribución 4.0 Internacional
    Documento(s) sujeto(s) a una licencia Creative Commons Atribución 4.0 Internacional
    Arquivos deste item
    Nombre:
    Valldeoriola-npjpd_2021.pdf
    Tamaño:
    1.165Mb
    Formato:
    Adobe PDF
    Thumbnail
    Visualizar/Abrir

    Métricas

    Citas

    Academic Search
    15
    CITATIONS
    15 total citations on Dimensions.
    15 Total citations
    12 Recent citations
    5.72 Field Citation Ratio
    1.71 Relative Citation Ratio
    Ver estadísticas de uso

    Exportar

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis
    Mostrar registro completo